We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here

News

Exciting advancements in the field of mantle cell lymphoma

Monday, August 7, 2017

John P. Leonard, M.D., professor of medicine, spoke to OncLive about some of the exciting advancements taking place in the field of mantle cell lymphoma (MCL).

In the MCL landscape, the BTK inhibitor ibrutinib (Imbruvica) has made a big difference for patients in improving their outcomes, Leonard explains.

Additionally, researchers are learning more about sub-classifying the MCL population, and the future is going to involve more combinations with ibrutinib. These include regimens with venetoclax (Venclexta), cell cycle inhibitors, or other novel compounds to try to minimize or treat resistance as well as extend the duration of remissions, he adds.